You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR BENAZEPRIL HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Benazepril Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00136773 ↗ Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus Completed Novartis Phase 4 2003-04-01 Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.
NCT00136851 ↗ Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension Completed Novartis Pharmaceuticals Phase 4 2004-12-01 This trial is designed to study the efficacy of an amlodipine besylate/benazepril treatment regimen versus an amlodipine treatment regimen in the treatment of severe hypertension.
NCT00139555 ↗ Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension Completed Novartis Phase 4 2004-07-01 Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.
NCT00170950 ↗ Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension Terminated Novartis Phase 3 2003-10-01 A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
NCT00171119 ↗ A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril Terminated Novartis Pharmaceuticals Phase 4 2004-01-01 The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
NCT00171366 ↗ A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril. Completed Pfizer Phase 3 2004-07-01 Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to amlodipine monotherapy in patients with non-essential hypertension, not controlled on amlodipine alone.
NCT00171366 ↗ A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril. Completed Novartis Phase 3 2004-07-01 Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to amlodipine monotherapy in patients with non-essential hypertension, not controlled on amlodipine alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Benazepril Hydrochloride

Condition Name

Condition Name for Benazepril Hydrochloride
Intervention Trials
Hypertension 16
Healthy 11
Proteinuria 4
Diabetes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Benazepril Hydrochloride
Intervention Trials
Hypertension 14
Diabetes Mellitus 6
Proteinuria 4
Albuminuria 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Benazepril Hydrochloride

Trials by Country

Trials by Country for Benazepril Hydrochloride
Location Trials
United States 28
Italy 14
China 8
Canada 2
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Benazepril Hydrochloride
Location Trials
New Jersey 5
North Carolina 4
North Dakota 3
West Virginia 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Benazepril Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Benazepril Hydrochloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Benazepril Hydrochloride
Clinical Trial Phase Trials
Completed 33
Terminated 7
Active, not recruiting 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Benazepril Hydrochloride

Sponsor Name

Sponsor Name for Benazepril Hydrochloride
Sponsor Trials
Novartis 6
Dr. Reddy's Laboratories Limited 4
Mylan Pharmaceuticals 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Benazepril Hydrochloride
Sponsor Trials
Industry 28
Other 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Benazepril Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction to Benazepril Hydrochloride

Benazepril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor, widely used in the treatment of hypertension and chronic renal disease. Initially developed by Novartis AG, it has been a cornerstone in cardiovascular therapy since its first approval in the US on June 25, 1991[1].

Mechanism and Therapeutic Use

Benazepril hydrochloride works by inhibiting the angiotensin-converting enzyme, which is crucial in the renin-angiotensin-aldosterone system (RAAS). This inhibition leads to a decrease in blood pressure and reduces the strain on the heart, making it an effective treatment for hypertension and related cardiovascular diseases[1].

Clinical Trials Update

While there are no recent clinical trials specifically focused on benazepril hydrochloride itself, the ongoing research in cardiovascular diseases and hypertension often involves ACE inhibitors like benazepril. For instance, clinical trials on other cardiovascular treatments sometimes include ACE inhibitors as part of the treatment regimen to manage comorbid conditions.

However, it's worth noting that clinical trials in related areas, such as those on other cardiovascular medications, can provide insights into the broader therapeutic landscape in which benazepril hydrochloride operates. For example, trials on new formulations or combination therapies may include ACE inhibitors as a standard treatment arm[4].

Market Analysis

Global Market Size and Growth

The global market for benazepril hydrochloride is projected to show a promising growth trajectory. In 2023, the market size was valued at around USD 2.1 billion and is forecasted to reach approximately USD 3.1 billion by 2032, with an estimated compound annual growth rate (CAGR) of 4.5% from 2024 to 2032[2].

Regional Outlook

  • North America: This region holds a significant share of the benazepril hydrochloride market, driven by high healthcare expenditure, advanced healthcare infrastructure, and a high prevalence of hypertension and cardiovascular diseases. North America accounted for approximately 35% of the global market in 2023 and is projected to grow at a CAGR of 3.8% during the forecast period[2].
  • Europe: Europe is another major market, with countries like Germany, France, and the UK leading in terms of market share. The region's aging population and increasing incidence of chronic diseases are key factors driving market growth. Europe accounted for approximately 28% of the global market in 2023 and is projected to grow at a CAGR of 3.5% during the forecast period[2].
  • Asia Pacific: This region is expected to witness the fastest growth in the benazepril hydrochloride market. In 2023, the region accounted for approximately 22% of the global market, with countries like China, India, and Japan being major contributors. The market in the Asia Pacific is projected to grow at a CAGR of 6.2%, reaching around USD 800 million by 2032[2].

Driving Factors

The growth of the benazepril hydrochloride market is primarily fueled by several key factors:

  • Increasing Prevalence of Hypertension: According to the World Health Organization, hypertension affects more than 1.28 billion people globally, making it a major risk factor for cardiovascular diseases[2].
  • Advances in Pharmaceutical Formulations: Continuous research and development efforts are leading to the introduction of new drug formulations and advanced delivery systems, enhancing the therapeutic efficacy and safety profiles of benazepril hydrochloride[5].
  • Rising Awareness and Healthcare Spending: Increasing awareness about cardiovascular health and the adoption of preventative measures, coupled with rising healthcare expenditure, are driving the demand for effective antihypertensive medications like benazepril hydrochloride[3].

Distribution Channels

The market is also influenced by various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels play a crucial role in making benazepril hydrochloride accessible to a wider patient population[2].

Market Projections

Future Directions

The benazepril hydrochloride market is poised for substantial growth driven by several factors:

  • Innovations in Formulations and Delivery Systems: New drug formulations and advanced delivery systems are expected to enhance the therapeutic efficacy and safety profiles of benazepril hydrochloride, driving market growth[5].
  • Generic Competition: The introduction of generic versions of benazepril hydrochloride has made the drug more affordable and accessible, leading to increased adoption and market growth. Generic competition also stimulates innovation and price competition in the market[5].
  • Expanding Healthcare Infrastructure: Emerging markets are experiencing rapid growth in healthcare infrastructure, leading to increased availability and use of benazepril hydrochloride. This expansion is expected to drive significant market growth as more patients in these regions gain access to effective hypertension treatments[5].

Market Size Projections

By 2032, the global benazepril hydrochloride market is expected to reach approximately USD 3.1 billion, growing at a CAGR of 4.5% from 2024 to 2032. Another projection suggests the market could reach USD 147.75 billion by 2031, growing at a CAGR of 5% from 2024 to 2031, although this figure seems to be an overestimation compared to other reports[2][3].

Key Takeaways

  • Growing Demand: The increasing prevalence of hypertension and related cardiovascular diseases is driving the demand for benazepril hydrochloride.
  • Regional Growth: North America, Europe, and the Asia Pacific are key regions driving market growth, with the Asia Pacific expected to witness the fastest growth.
  • Innovations: Advances in pharmaceutical formulations and delivery systems are enhancing the market.
  • Affordability: Generic versions of benazepril hydrochloride have increased its accessibility and adoption.
  • Healthcare Infrastructure: Expanding healthcare infrastructure in emerging markets is a significant growth factor.

FAQs

What is benazepril hydrochloride used for?

Benazepril hydrochloride is used to treat hypertension and chronic renal disease by inhibiting the angiotensin-converting enzyme.

What is the current market size of benazepril hydrochloride?

The global market size for benazepril hydrochloride was valued at around USD 2.1 billion in 2023.

What is the projected growth rate of the benazepril hydrochloride market?

The market is projected to grow at a CAGR of around 4.5% from 2024 to 2032.

Which regions are driving the growth of the benazepril hydrochloride market?

North America, Europe, and the Asia Pacific are the key regions driving market growth, with the Asia Pacific expected to witness the fastest growth.

What factors are driving the growth of the benazepril hydrochloride market?

The growth is driven by increasing prevalence of hypertension, advances in pharmaceutical formulations, rising awareness about cardiovascular health, and expanding healthcare infrastructure in emerging markets.

Sources

  1. Synapse by Patsnap: Benazepril Hydrochloride - Drug Targets, Indications, Patents.
  2. Dataintelo: Benazepril Hydrochloride Market Research Report 2032.
  3. Market Research Intellect: Benazepril Hydrochloride Market Size and Projections.
  4. AstraZeneca Clinical Trials: Disclaimer - AstraZeneca Clinical Trials.
  5. Market Research Intellect: Future Directions in the Benazepril Hydrochloride Market.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.